CHM enters AU$30 million Equity placement agreement with L1 Capital

Chimeric Therapeutics Limited (ASX: CHM) announced that it had entered into an equity placement agreement with L1 Capital Global Opportunities Master Fund to raise up to AU$30 million. L1 Capital is a leading global investor, which is based in Melbourne, Australia, with more than AU$5 billion in funds under management. The fund raised through the equity placement will help to strengthen the Company’s balance sheet in the future as Chimeric rapidly moves forward with a portfolio of four Phase 1 clinical trials.

The equity placement agreement includes an initial placement of AU$500,000 in ordinary shares at AU$0.10 per share, and 15,000,000 unlisted options which are exercisable at AU$0.255 each, expiring on 31 March 2024, to be issued within seven days, and up to an additional AU$30 million in ordinary share placements will be done over a 24-month period.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au